On November 12, Rocket Lab USA, Inc. fell 4.04% in Pre-Market Trading, trading at $63.5 per share, with turnover of $23.1246 million.
The move coincided with continued market digestion of modest analyst target-price cuts, weaker-than-expected third-quarter profitability, the proposed roughly $8 billion Iridium transaction, and a recent $1.05 million January 2027 $80 call sale that pointed to capped-upside positioning.
Recent updates showed Morgan Stanley lowered its price target to $103 from $105 while maintaining an Overweight rating, and Needham cut its target to $100. Rocket Lab USA, Inc. reported third-quarter revenue of $267.8 million, up 73% year over year and above expectations, but posted a per-share loss of $0.12, worse than expected. The company is also still being evaluated through the lens of its proposed Iridium acquisition and the commercialization path for Neutron, which some analysts still view positively over the longer term.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments